<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0100279'>Ulcerative colitis</z:hpo> (UC) patients may develop <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), especially with <z:e sem="disease" ids="C0868908" disease_type="Disease or Syndrome" abbrv="">pancolitis</z:e> and longer UC duration </plain></SENT>
<SENT sid="1" pm="."><plain>The question whether <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with underlying UC has a dismal prognosis remains unsettled </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We performed an electronic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> base documentation (eTBD) search of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and UC patients at our department to address whether (1) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prognosis is impaired and (2) defined risks can be determined </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: With the inclusion of an index patient with UC and unresponsive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 20 additional patients were identified via eTBD </plain></SENT>
<SENT sid="4" pm="."><plain>Chemotherapy response was less substantial, with complete response or stable disease in 3 patients each, but rapidly progressing or refractory disease in 15/21 patients </plain></SENT>
<SENT sid="5" pm="."><plain>12 out of the 21 patients died </plain></SENT>
<SENT sid="6" pm="."><plain>Our hazard ratio analysis revealed International Union against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> (UICC) stage IV and III disease, grade 3 tumors, longer latency from UC to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and age &gt;60 years as potential risks </plain></SENT>
<SENT sid="7" pm="."><plain>Median progression-free survival and overall survival were 48 and 82 months, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Time from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> dissemination to <z:hpo ids='HP_0011420'>death</z:hpo> was 10 months </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in UC patients is not necessarily impaired, albeit chemotherapy response with disseminated disease may be unfavorable </plain></SENT>
<SENT sid="10" pm="."><plain>Our data should be enlarged by subsequent analyses to better elucidate whether response in UC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is more challenging and defined risks can be confirmed </plain></SENT>
</text></document>